|
1
|
Jemal A, Bray F, Center MM, Ferlay J, Ward
E and Forman D: Global cancer statistics. CA Cancer J Clin.
61:69–90. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Cunningham D, Humblet Y, Siena S, Khayat
D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype
C, et al: Cetuximab monotherapy and cetuximab plus irinotecan in
irinotecan-refractory metastatic colorectal cancer. N Engl J Med.
351:337–345. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, et al: Bevacizumab plus irinotecan, fluorouracil, and
leucovorin for metastatic colorectal cancer. N Engl J Med.
350:2335–2342. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Rovcanin B, Ivanovski I, Djuric O, Nikolic
D, Petrovic J and Ivanovski P: Mitotic crossover - an evolutionary
rudiment which promotes carcinogenesis of colorectal carcinoma.
World J Gastroenterol. 20:12522–12525. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Oppenheimer JH: The molecular basis of
thyroid hormone action: Scattered pieces of jigsaw puzzle. Prog
Clin Biol Res. 74:45–55. 1981.PubMed/NCBI
|
|
6
|
Mangelsdorf DJ, Thummel C, Beato M,
Herrlich P, Schütz G, Umesono K, Blumberg B, Kastner P, Mark M,
Chambon P, et al: The nuclear receptor superfamily: The second
decade. Cell. 83:835–839. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Muñoz A and Bernal J: Biological
activities of thyroid hormone receptors. Eur J Endocrinol.
137:433–445. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng SY: Multiple mechanisms for
regulation of the transcriptional activity of thyroid hormone
receptors. Rev Endocr Metab Disord. 1:9–18. 2000. View Article : Google Scholar
|
|
9
|
Bradley DJ, Towle HC and Young WS III:
Spatial and temporal expression of alpha- and beta-thyroid hormone
receptor mRNAs, including the beta 2-subtype, in the developing
mammalian nervous system. J Neurosci. 12:2288–2302. 1992.PubMed/NCBI
|
|
10
|
Lazar MA: Thyroid hormone receptors:
Multiple forms, multiple possibilities. Endocr Rev. 14:184–193.
1993.PubMed/NCBI
|
|
11
|
Tagami T, Nakamura H, Sasaki S, Miyoshi Y
and Imura H: Estimation of the protein content of thyroid hormone
receptor alpha 1 and beta 1 in rat tissues by western blotting.
Endocrinology. 132:275–279. 1993.PubMed/NCBI
|
|
12
|
González-Sancho JM, García V, Bonilla F
and Muñoz A: Thyroid hormone receptors/THR genes in human cancer.
Cancer Lett. 192:121–132. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Lin KH, Shieh HY, Chen SL and Hsu HC:
Expression of mutant thyroid hormone nuclear receptors in human
hepatocellular carcinoma cells. Mol Carcinog. 26:53–61. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Puzianowska-Kuznicka M, Nauman A, Madej A,
Tanski Z, Cheng S and Nauman J: Expression of thyroid hormone
receptors is disturbed in human renal clear cell carcinoma. Cancer
Lett. 155:145–152. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Kamiya Y, Puzianowska-Kuznicka M, McPhie
P, Nauman J, Cheng SY and Nauman A: Expression of mutant thyroid
hormone nuclear receptors is associated with human renal clear cell
carcinoma. Carcinogenesis. 23:25–33. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Silva JM, Domínguez G, González-Sancho JM,
García JM, Silva J, García-Andrade C, Navarro A, Muñoz A and
Bonilla F: Expression of thyroid hormone receptor/erbA genes is
altered in human breast cancer. Oncogene. 21:4307–4316. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Safer JD, Colan SD, Fraser LM and
Wondisford FE: A pituitary tumor in a patient with thyroid hormone
resistance: A diagnostic dilemma. Thyroid. 11:281–291. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ando S, Sarlis NJ, Oldfield EH and Yen PM:
Somatic mutation of TRbeta can cause a defect in negative
regulation of TSH in a TSH-secreting pituitary tumor. J Clin
Endocrinol Metab. 86:5572–5576. 2001.PubMed/NCBI
|
|
19
|
Puzianowska-Kuznicka M, Krystyniak A,
Madej A, Cheng SY and Nauman J: Functionally impaired TR mutants
are present in thyroid papillary cancer. J Clin Endocrinol Metab.
87:1120–1128. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Martínez-Iglesias O, Garcia-Silva S,
Tenbaum SP, Regadera J, Larcher F, Paramio JM, Vennström B and
Aranda A: Thyroid hormone receptor beta1 acts as a potent
suppressor of tumor invasiveness and metastasis. Cancer Res.
69:501–509. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Zhu XG, Zhao L, Willingham MC and Cheng
SY: Thyroid hormone receptors are tumor suppressors in a mouse
model of metastatic follicular thyroid carcinoma. Oncogene.
29:1909–1919. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Chen RN, Huang YH, Yeh CT, Liao CH and Lin
KH: Thyroid hormone receptors suppress pituitary tumor transforming
gene 1 activity in hepatoma. Cancer Res. 68:1697–1706. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ringel MD, Hayre N, Saito J, Saunier B,
Schuppert F, Burch H, Bernet V, Burman KD, Kohn LD and Saji M:
Overexpression and overactivation of Akt in thyroid carcinoma.
Cancer Res. 61:6105–6111. 2001.PubMed/NCBI
|
|
24
|
Kim CS, Vasko VV, Kato Y, Kruhlak M, Saji
M, Cheng SY and Ringel MD: AKT activation promotes metastasis in a
mouse model of follicular thyroid carcinoma. Endocrinology.
146:4456–4463. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Dent P: Crosstalk between ERK, AKT, and
cell survival. Cancer Biol Ther. 15:245–246. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Suzuki H, Willingham MC and Cheng SY: Mice
with a mutation in the thyroid hormone receptor beta gene
spontaneously develop thyroid carcinoma: A mouse model of thyroid
carcinogenesis. Thyroid. 12:963–969. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Guigon CJ, Zhao L, Willingham MC and Cheng
SY: PTEN deficiency accelerates tumour progression in a mouse model
of thyroid cancer. Oncogene. 28:509–517. 2009. View Article : Google Scholar
|
|
28
|
Lu C, Willingham MC, Furuya F and Cheng
SY: Activation of phosphatidylinositol 3-kinase signaling promotes
aberrant pituitary growth in a mouse model of thyroid-stimulating
hormone-secreting pituitary tumors. Endocrinology. 149:3339–3345.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Furuya F, Lu C, Guigon CJ and Cheng SY:
Nongenomic activation of phosphatidylinositol 3-kinase signaling by
thyroid hormone receptors. Steroids. 74:628–634. 2009. View Article : Google Scholar
|
|
30
|
Hörkkö TT, Tuppurainen K, George SM,
Jernvall P, Karttunen TJ and Mäkinen MJ: Thyroid hormone receptor
beta1 in normal colon and colorectal cancer-association with
differentiation, polypoid growth type and K-ras mutations. Int J
Cancer. 118:1653–9. 2006. View Article : Google Scholar
|
